Litcius/Paper detail

Risks and Benefits of Janus Kinase Inhibitors in Rheumatoid Arthritis — Past, Present, and Future

Jasvinder A. Singh

2022New England Journal of Medicine22 citationsDOI

Topics & Concepts

Rheumatoid arthritisMedicineJanus kinaseTofacitinibImmunologyImmune systemTyrosine kinaseKinaseAutoimmune diseaseCancer researchJanus kinase inhibitorClinical trialJanus kinase 3Janus kinase 2Internal medicineBioinformaticsDiseaseArthritisImmunopathologyRheumatoid Arthritis Research and TherapiesCytokine Signaling Pathways and InteractionsChronic Lymphocytic Leukemia Research